We show that inhibition of HDAC1,2 is sufficient to overcome the survival advantage mediated by EZH2 and BBAP enzymes in the refractory EZH2GOF DLBCL cells (Figure 10). The gene discussed is DTX3L; the disease is diffuse large B-cell lymphoma.